MCL coexpression mm9:288

Phase1 CAGE Peaks

	Short description
Mm9::chr11:6505664..6505673,-	p@chr11:6505664..6505673 -
Mm9::chr11:72020498..72020513,-	p@chr11:72020498..72020513 -
Mm9::chr12:30220046..30220070,+	p6@Myt1l
Mm9::chr12:30220074..30220102,+	p3@Myt1l
Mm9::chr15:78541224..78541236,-	p@chr15:78541224..78541236 -
Mm9::chr17:37187549..37187560,+	p7@Gabbr1
Mm9::chr18:64424264..64424293,+	p@chr18:64424264..64424293 +
Mm9::chr18:64424505..64424516,+	p@chr18:64424505..64424516 +
Mm9::chr18:67293367..67293388,+	p5@Gnal
Mm9::chr18:86564164..86564174,+	p4@Neto1
Mm9::chr18:86564576..86564625,+	p3@Neto1
Mm9::chr18:86564667..86564677,+	p8@Neto1
Mm9::chr1:89407123..89407159,-	p5@Ngef
Mm9::chr2:115891770..115891799,-	p25@Meis2
Mm9::chr2:151907604..151907629,+	p4@Scrt2
Mm9::chr2:156137489..156137502,+	p@chr2:156137489..156137502 +
Mm9::chr3:103379161..103379178,+	p3@Syt6
Mm9::chr4:129662027..129662032,+	p6@Bai2
Mm9::chr4:129662053..129662065,+	p3@Bai2
Mm9::chr4:24357985..24358002,-	p@chr4:24357985..24358002 -
Mm9::chr5:121460094..121460135,-	p5@Rph3a
Mm9::chr5:130924685..130924700,+	p3@Caln1
Mm9::chr7:64845896..64845923,+	p2@Gabrb3
Mm9::chr7:64845935..64845942,+	p8@Gabrb3
Mm9::chr7:94732650..94732683,+	p3@Grm5
Mm9::chr9:44290614..44290635,+	p@chr9:44290614..44290635 +
Mm9::chr9:62385142..62385161,-	p9@Coro2b
Mm9::chr9:62385178..62385187,-	p17@Coro2b
Mm9::chr9:79708145..79708172,-	p@chr9:79708145..79708172 -

Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data

---

GO ID	GO name	FDR corrected p-value
GO:0008067	metabotropic glutamate, GABA-B-like receptor activity	0.0174155064064894
GO:0030054	cell junction	0.0174155064064894
GO:0016917	GABA receptor activity	0.0174155064064894
GO:0008066	glutamate receptor activity	0.0324413044456912
GO:0008021	synaptic vesicle	0.0376436272770898

Relative expression of the co-expression cluster over median <br>Analyst:

---

"{{{coexpression_dpi_cluster_scores_median}}}" is not a number.

Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>

---

Cell Type

Ontology term	p-value	n

Uber Anatomy

Ontology term	p-value	n

Disease

Ontology term	p-value	n

TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data

---

Novel motifs

JASPAR motifs

Motifs	-log10(p-value)
{{{tfbs_overrepresentation_jaspar}}}